Siglec 1 and 2 as potential biomarkers in autoimmune disease

Amanda Eakin, Michael Bustard, Cathy McGeough, Tahanver Ahmed, AJ Bjourson, David Gibson

Research output: Contribution to journalArticlepeer-review

15 Citations (Scopus)


Autoimmune diseases (AD) are currently treated with anti-inflammatory and immunosuppressive drugs, aimed at reducing symptoms of disease in order to improve quality of life for patients. However, for a significant number of patients these therapies are ineffective, leading to an increased risk of irreversible damage and eventual disability in certain cases. Growing evidence has implicated glycosylated proteins and their cognate receptors in modulation of the autoimmune response. This review will summarise these findings with particular focus on Siglec-1 and -2 involvement in AD. Fluctuations in these glycosylation dependent pathways could act as sentinels of disease activity or drug responses. If validated, protein modification and cellular response markers could help clinicians achieve remission earlier.
Original languageEnglish
JournalPROTEOMICS - Clinical Applications
Early online date11 Jan 2016
Publication statusPublished (in print/issue) - 1 Jun 2016


  • Glycosylation
  • Immune tolerance
  • Siglec


Dive into the research topics of 'Siglec 1 and 2 as potential biomarkers in autoimmune disease'. Together they form a unique fingerprint.

Cite this